-
The dilemma of the role of the non‐HLA antibodies in AMR Clin. Transplant. (IF 2.1) Pub Date : 2024-03-15 Maria T. Gamero, Patricia Uber, Yevgeniy Brailovsky, Gregory Gibson, Eduardo Rame, Rene Alvarez, Yanping Huang, Indranee Rajapreyar
-
Risk factors and outcomes of bloodstream infection from a urinary source in kidney transplant recipients Clin. Transplant. (IF 2.1) Pub Date : 2024-03-15 Emily M. Eichenberger, Maja Wichhart Donzo, Rebecca Anderson, Geeta Karadkhele, Stephanie M. Pouch, Christian P. Larsen
BackgroundBacteriuria is common among kidney transplant recipients (KTR). Risk factors and outcomes associated with bloodstream infection due to a urinary source (BSIU) in KTR are poorly understood.MethodsThis single center case‐control study from 2010 to 2022 compared KTR with BSIU to those with bacteria without bloodstream infection (BU). Multivariable logistic regression identified BSIU risk factors
-
Does lung procurement and exposure to Perfadex impact heart transplantation outcomes Clin. Transplant. (IF 2.1) Pub Date : 2024-03-15 David Blitzer, David A. Baran, Seth Lirette, Hannah Copeland
IntroductionSome studies have shown increased incidence of Primary Graft Dysfunction (PGD) after heart and lung procurement for heart transplant recipients. There have been limited investigations of the impact of lung procurement on heart procurement and the potential effects of the exposure to the type of lung preservation solution, the volume of the lung preservation solution and adequacy of decompression
-
Clinical performance of the iPREDICTLIVING tool for the prediction of the post‐transplant recipient and living donor outcomes in a European cohort Clin. Transplant. (IF 2.1) Pub Date : 2024-03-15 Manuela Almeida, Catarina Ribeiro, José Silvano, Sofia Pedroso, Sandra Tafulo, La Salete Martins, Miguel Ramos, Jorge Malheiro
A living donor kidney transplant (LDKT) is the best treatment for ESRD. A prediction tool based on clinical and demographic data available pre‐KT was developed in a Norwegian cohort with three different models to predict graft loss, recipient death, and donor candidate's risk of death, the iPREDICTLIVING tool. No external validations are yet available. We sought to evaluate its predictive performance
-
The role of anticomplement therapy in the management of the kidney allograft Clin. Transplant. (IF 2.1) Pub Date : 2024-03-15 Mehmet Kanbay, Sidar Copur, Zeynep Y. Yilmaz, Dilek Ertoy Baydar, Ilmay Bilge, Caner Susal, Burak Kocak, Alberto Ortiz
As the number of patients living with kidney failure grows, the need also grows for kidney transplantation, the gold standard kidney replacement therapy that provides a survival advantage. This may result in an increased rate of transplantation from HLA‐mismatched donors that increases the rate of antibody‐mediated rejection (AMR), which already is the leading cause of allograft failure. Plasmapheresis
-
Use of hydroxocobalamin to treat intraoperative vasoplegic syndrome refractory to vasopressors and methylene blue during liver transplantation Clin. Transplant. (IF 2.1) Pub Date : 2024-03-15 Sher‐Lu Pai, Klaus D. Torp, Vianca C. Insignares, Samuel DeMaria, Chris R. Giordano, Ilana I. Logvinov, Zhuo Li, Ryan Chadha, Stephen Aniskevich
IntroductionFor patients with catecholamine‐resistant vasoplegic syndrome (VS) during liver transplantation (LT), treatment with methylene blue (MB) and/or hydroxocobalamin (B12) has been an acceptable therapy. However, data on the effectiveness of B12 is limited to case reports and case series.MethodsWe retrospectively reviewed records of patients undergoing LT from January 2016 through March 2022
-
Lung transplant airway complications treated with biodegradable airway stents: The Dutch multi‐center experience Clin. Transplant. (IF 2.1) Pub Date : 2024-03-15 Roel van Pel, Tji Gan, Johannes M. A. Daniels, Dieuwertje Ruigrok, Merel E. Hellemons, Karin Klooster, Dirk‐Jan Slebos
IntroductionTreatment of post lung‐transplant airway complications is challenging, and treatment with conventional airway stents is associated with adverse events. More recently, biodegradable airway stents (BDS) have been introduced and may be used to reduce these adverse events. In this study we explore the feasibility of treatment with BDS post lung transplant.MethodsAll patients treated with BDS
-
Determinants of hyperparathyroidism in children after kidney transplantation Clin. Transplant. (IF 2.1) Pub Date : 2024-03-14 Wendy Glaberson, Wacharee Seeherunvong, Jeffrey J. Gaynor, Chryso Katsoufis, Marissa Defreitas, Yong Bao, Michael Freundlich, Gaetano Ciancio, Carolyn Abitbol, Jayanthi Chandar
IntroductionHyperparathyroidism (HPT) can contribute to metabolic bone disease following kidney transplantation. We evaluated post‐transplant trends in intact parathyroid hormone (iPTH) and determined predictors of HPT in pediatric kidney transplant (KTx) recipients.MethodsIn this single‐center study, retrospective data were collected on 88 children from 2013 to 2019. Data collected included dialysis
-
Acetylsalicylic acid use and development of cardiac allograft vasculopathy: A national prospective study using highly automated 3‐D optical coherence tomography analysis Clin. Transplant. (IF 2.1) Pub Date : 2024-03-13 Lucie Mayerova, Peter Wohlfahrt, Milan Sonka, Zhi Chen, Josef Kautzner, Vojtech Melenovsky, Vladimir Karmazin, Ivan Malek, Helena Bedanova, Ales Tomasek, Eva Ozabalova, Jan Krejci, Tomas Kovarnik, Michal Pazdernik
BackgroundThere is conflicting evidence on the role of acetylsalicylic acid (ASA) use in the development of cardiac allograft vasculopathy (CAV).MethodsA nationwide prospective two‐center study investigated changes in the coronary artery vasculature by highly automated 3‐D optical coherence tomography (OCT) analysis at 1 month and 12 months after heart transplant (HTx). The influence of ASA use on
-
The impact of active cytomegalovirus infection on donor‐derived cell‐free DNA testing in heart transplant recipients Clin. Transplant. (IF 2.1) Pub Date : 2024-03-13 Amit H. Alam, Johanna Van Zyl, Hira I. Shakoor, Dana Farsakh, Ahmad B. Abdelrehim, Neville Maliakkal, Aayla K. Jamil, Raksha Patel, Joost Felius, Staci McKean, Shelley A. Hall
BackgroundLittle is known about the relationship between cytomegalovirus (CMV) infections and donor‐derived cell‐free DNA (dd‐cfDNA) in heart transplant recipients.MethodsIn our study, CMV and dd‐cfDNA results were prospectively collected on single‐organ heart transplant recipients. If the CMV study was positive, a CMV study with dd‐cfDNA was repeated 1‐3 months later. The primary aim was to compare
-
Implications of drug intoxication on donor utilization and outcomes in liver transplantation Clin. Transplant. (IF 2.1) Pub Date : 2024-03-08 Michie Adjei, Steven A. Wisel, Ju Dong Yang, Nicholas N. Nissen, Irene K. Kim, Justin A. Steggerda
IntroductionThis study evaluates the implications of drug intoxication (DI) on donor utilization and outcomes in liver transplantation (LT).MethodsThe UNOS STAR database was evaluated for all potential donors and adult, first‐time, whole LT between 2005 and 2019. Logistic regression analyses evaluated liver utilization; proportional hazards modeling assessed risk of 1‐year graft loss.ResultsA total
-
-
Early outcomes associated with de novo once‐daily extended‐release versus twice‐daily immediate‐release tacrolimus in a predominantly African American kidney transplant population: A single‐center observational study Clin. Transplant. (IF 2.1) Pub Date : 2024-03-07 Margaret M. Romine, David B. Leeser, Karen Kennamer, Catherine Nguyen, Heather Jones, Kristel McLawhorn, Scott Kendrick, William Irish
IntroductionThe purpose of this study was to compare early outcomes of de novo LCPT (once‐daily extended‐release tacrolimus) to IR TAC (twice‐daily immediate‐release tacrolimus) in a predominantly African American (AA) adult kidney transplant population.MethodsThis is a single center, retrospective cohort study. Patients were divided into two cohorts: IR TAC (administered between January 1, 2017, and
-
The effect of primary renal disease upon outcomes after renal transplant Clin. Transplant. (IF 2.1) Pub Date : 2024-03-07 Shona Garland, Kairi Pullerits, Chukwuma A Chukwu, Rajkumar Chinnadurai, Rachel Middleton, Philip A Kalra
BackgroundThis study investigated whether nature of primary renal disease affects clinical outcomes after renal transplantation at a single center in the United Kingdom.MethodsThis was a retrospective cohort study of 961 renal transplant recipients followed up at a large renal center from 2000 to 2020. Separation of diseases responsible for end‐stage kidney disease included glomerulonephritis, diabetic
-
COVID-19 infection in patients with history of pediatric heart transplant in Germany, Austria, and Switzerland Clin. Transplant. (IF 2.1) Pub Date : 2024-03-06 Sarah Ulrich, Christian Balmer, Kolja Becker, Josefin Bruhs, Friederike Danne, Volker Debus, Leonie Dewein, Stefano Di-Bernardo, Ulrike Doll, Thilo Fleck, Theodor Tirilomis, Martin Glöckler, Maria Grafmann, Sabine Greil, Urte Grosser, Patrick Saur, Susanne Skrzypek, Michael Steinmetz
COVID-19 is a heterogenous infection—asymptomatic to fatal. While the course of pediatric COVID-19 infections is usually mild or even asymptomatic, individuals after adult heart transplantation are at high risk of a severe infection. We conducted a retrospective, multicenter survey of 16 pediatric heart transplant centers in Germany, Austria and Switzerland to evaluate the risk of a severe COVID-19
-
Single center utilization and post‐transplant outcomes of thoracoabdominal normothermic regional perfusion deceased cardiac donor organs Clin. Transplant. (IF 2.1) Pub Date : 2024-03-06 Jennifer D. Motter, Ian S. Jaffe, Nader Moazami, Deane E. Smith, Zachary N. Kon, Greta L. Piper, Philip M. Sommer, Alex Reyentovich, Stephanie H. Chang, Imad Aljabban, Robert A. Montgomery, Dorry L. Segev, Allan B. Massie, Bonnie E. Lonze
IntroductionThoracoabdominal normothermic regional perfusion (TA‐NRP) following cardiac death is an emerging multivisceral organ procurement technique. Recent national studies on outcomes of presumptive TA‐NRP‐procured organs are limited by potential misclassification since TA‐NRP is not differentiated from donation after cardiac death (DCD) in registry data.MethodsWe studied 22 donors whose designees
-
Use of induction therapy post‐heart transplantation: Clinical practice recommendations based on systematic review and network meta‐analysis of evidence Clin. Transplant. (IF 2.1) Pub Date : 2024-03-06 Farid Foroutan, Gordon Guyatt, Josef Stehlik, Finn Gustafsson, Douglas Greig, Michael McDonald, Alejandro Mario Bertolotti, Lakshmi Kugathasan, Daniel G. Rayner, Carlos A. Cuello, Amanda Cook, Darko Zlatanoski, Sujivan Ram, Penny Demas‐Clarke, Stella Kozuszko, Ana Carolina Alba
BackgroundThe use of induction therapy (IT) agents in the early post‐heart transplant period remains controversial. The following recommendations aim to provide guidance on the use of IT agents, including Basiliximab and Thymoglobulin, as part of routine care in heart transplantation (HTx).MethodsWe recruited an international, multidisciplinary panel of 15 stakeholders, including patient partners,
-
Peri‐operative and long‐term outcomes of kidney transplantation in patients with cystic fibrosis Clin. Transplant. (IF 2.1) Pub Date : 2024-02-24 John A. O'Kelly, Fatimah Alaya, Niall F. Davis, Dilly Little, Ponnusamy Mohan
IntroductionThere is a lack of data regarding the peri‐operative and long‐term outcomes of kidney transplantation in cystic fibrosis (CF) patients. Herein, we report the peri‐operative and long‐term outcomes of kidney transplantation in CF patients.Materials and methodsAll CF patients who received a kidney transplant at the national kidney transplant center between 1993 and 2022 were identified. Recipients
-
Do pre‐transplant cultural factors predict health‐related quality of life after kidney transplantation? Clin. Transplant. (IF 2.1) Pub Date : 2024-02-24 Jamie M. Loor, C. Graham Ford, Yuridia Leyva, Samuel Swift, Yue Harn Ng, Yiliang Zhu, Mary Amanda Dew, J. Devin Peipert, Mark L. Unruh, Emilee Croswell, Kellee Kendall, Chethan Puttarajappa, Ron Shapiro, Larissa Myaskovsky
BackgroundPost‐transplant health‐related quality of life (HRQOL) is associated with health outcomes for kidney transplant (KT) recipients. However, pretransplant predictors of improvements in post‐transplant HRQOL remain incompletely understood. Namely, important pretransplant cultural factors, such as experience of discrimination, perceived racism in healthcare, or mistrust of the healthcare system
-
Long‐term post‐transplantation outcomes in patients with hypertrophic cardiomyopathy: Single‐center 35‐year experience Clin. Transplant. (IF 2.1) Pub Date : 2024-02-21 Matylda Mazur, Geetha Bhat, Eric Popjes, Robert Dowling, Howard J. Eisen
BackgroundHeart transplantation (HT) is the only option for most patients with end‐stage heart failure and hypertrophic cardiomyopathy (HCM) who fail medical therapy. Data on the long‐term outcomes post‐transplant in HCM individuals remain scarce.MethodsWe analyzed data of 319 adult patients who underwent HT between 1984 and 2019. Patients were followed for cardiac allograft rejection, cardiac allograft
-
Impact of race‐neutral eGFR calculations on African American kidney transplant candidate wait time: A single center retrospective analysis Clin. Transplant. (IF 2.1) Pub Date : 2024-02-21 Rafael Khaim, Rachel Todd, Andrew Rosowicz, Ron Shapiro, Sander Florman, Leona Kim‐Schluger, Fasika Tedla
Race‐inclusive estimated glomerular filtration rate (eGFR) could contribute to racial disparity in access to kidney transplantation. The Organ Procurement and Transplantation Network (OPTN) issued a policy allowing waiting time modification for candidates affected by race‐inclusive eGFR calculations. Implementation of the new OPTN policy at the kidney transplant program of the Mount Sinai Hospital
-
Long‐term outcomes after COVID‐19 infection in transplant recipients Clin. Transplant. (IF 2.1) Pub Date : 2024-02-21 Kaitlyn L. Freels, Kapil K. Saharia, John W. Baddley, Nadiesda A. Costa, Silke V. Niederhaus
BackgroundLong‐term outcomes after COVID‐19 infection unique to solid organ transplant recipients (SOTR) are not published. We describe outcomes including readmission, allograft rejection, allograft dysfunction, allograft failure, and death.MethodsWe conducted a retrospective cohort study of mostly unvaccinated SOTR with COVID‐19 from March 2020 to November 2021. Disease severity was assigned by NIH
-
-
The prognosis of haploidentical hematopoietic stem cell transplantation in infants and patients under 3 years old with acute leukemia Clin. Transplant. (IF 2.1) Pub Date : 2024-02-20 Guan‐hua Hu, Xiao‐hui Zhang, Yu Wang, Lan‐ping Xu, Xin‐lin Hou, Yi‐fei Cheng, Xiao‐jun Huang
BackgroundThe role of allogeneic hematopoietic stem cell transplantation (allo‐HSCT) in patients <3 years of age remains controversial. Data on haploidentical donor (HID) transplants in this age group is limited.Patients and MethodsWe retrospectively analyzed the prognosis of 97 patients with acute leukemia aged <3 years who underwent HID transplantation at our institute.ResultsWith a median follow‐up
-
De novo hepatitis B infection following liver transplantation with core antibody positive grafts: The role of surface antibody status in guiding long‐term prophylaxis Clin. Transplant. (IF 2.1) Pub Date : 2024-02-20 Brad Busebee, Laura Myhre, Kristin Mara, Bashar Aqel, Timucin Taner, Kymberly D. Watt
Liver transplantation (LT) with hepatitis B core antibody (anti‐HBc) positive grafts to hepatitis B surface‐antigen (HBsAg) negative recipients is safe and has likely contributed to improvements in organ access over the years. The incidence of de novo hepatitis B infection (HBV) in these instances is low with appropriate prophylaxis and is affected by recipient immunologic status. There is debate as
-
Cannabis use is associated with reduced access to kidney transplantation and an increased risk of acute rejection post‐transplant Clin. Transplant. (IF 2.1) Pub Date : 2024-02-20 Sonia Rodríguez‐Ramírez, Evan Tang, Yanhong Li, Olusegun Famure, Istvan Mucsi, Sang Joseph Kim
BackgroundThe association between cannabis use and access to waitlisting, transplantation, and post‐transplant outcomes remains uncertain.MethodsPatients referred for kidney transplant (KT) to the University Health Network from January 1, 2003, to June 30, 2020, and followed until December 31, 2020, were included. Predictors of reported cannabis use were examined using a logistic regression model.
-
Outcomes after kidney transplant alone in patients with cirrhosis—A case‐control study Clin. Transplant. (IF 2.1) Pub Date : 2024-02-20 Rohit R. Nathani, Stephanie M. Rutledge, Carolina S. Villarroel, Ron Shapiro, Sander S. Florman, Fasika M. Tedla, Thomas D. Schiano, Gene Y. Im
BackgroundGuidelines recommend kidney transplant alone (KTA) in compensated cirrhosis based on a few small studies, but this is not widely performed despite its potential benefit to patients and the organ supply. Our aim was to determine the outcomes of KTA in patients with compensated cirrhosis.Study designFrom 1/2012 to 12/2021, outcomes in KTA recipients with compensated cirrhosis were retrospectively
-
Tixagevimab/cilgavimab for the prevention of COVID‐19 in solid organ transplant recipients Clin. Transplant. (IF 2.1) Pub Date : 2024-02-20 Emily Eribes, Cassandra Votruba, Tyler Tinkham, Angela Huang, Dan Ilges, Katie Kunze, Madeline Hudson
Tixagevimab/cilgavimab (tix/cil) received emergency use authorization in December 2021 for pre‐exposure prophylaxis against COVID‐19 in moderately to severely immunocompromised patients. Our study aimed to describe the incidence of COVID‐19 infection and assess the immunologic risks associated with tix/cil in kidney, pancreas, liver, and heart transplant recipients. Retrospective chart review was completed
-
A retrospective analysis of anticoagulant safety among heart transplant recipients undergoing endomyocardial biopsy Clin. Transplant. (IF 2.1) Pub Date : 2024-02-19 James Christian Stock, Jason Carlquist, Megan Melnyk, Sakima Smith, Indra Bole, Vaiibhav Patel, Sitaramesh Emani, Beth Foreman, Ayesha Hasan, Veronica Franco, Brent Charles Lampert, Garrie Joseph Haas, Ajay Vallakati, Jianing Ma, Jing Peng, Konstantinos Dean Boudoulas, Rami Kahwash
BackgroundTransvenous endomyocardial biopsy is an invasive procedure which is used to diagnose rejection following an orthotopic heart transplant. Endomyocardial biopsy is widely regarded as low risk with all‐cause complication rates below 5% in most safety studies. Following transplant, some patients require therapeutic anticoagulation. It is unknown whether anticoagulation increases endomyocardial
-
A quantitative assessment of renal function utilizing albuminuria in pediatric heart transplant recipients Clin. Transplant. (IF 2.1) Pub Date : 2024-02-19 Erik L. Frandsen, Richard A. Kronmal, Erin A. Albers, Joshua M. Friedland‐Little, Borah J. Hong, Katherine L. Spencer, Sangeeta R. Hingorani, Yuk M. Law
IntroductionKidney disease is common after pediatric heart transplantation. Serum creatinine‐based glomerular filtration rate is the most frequently reported measure of kidney function. Albuminuria is an additional marker of kidney dysfunction and is not well described in this population. In this study, we evaluate the prevalence and degree of albuminuria and describe clinical factors associated with
-
Effectiveness of combined plasma cell therapy and costimulation blockade based desensitization regimen in heart transplant candidates Clin. Transplant. (IF 2.1) Pub Date : 2024-02-19 Nadia Fida, Todd N. Eagar, Allison N. Yun, Alex W. Rogers, Duc T. Nguyen, Edward A. Graviss, Farhan Ishaq, Nicholas R. DiPaola, Ju Kim, Gorthi Janardhana, Mahwash Kassi, Rayan Yousefzai, Eric E. Suarez, Arvind Bhimaraj, Jill C. Krisl, Ashrith Guha
BackgroundDesensitization is one of the strategies to reduce antibodies and facilitate heart transplantation in highly sensitized patients. We describe our center's desensitization experience with combination of plasma cell (PC) depletion therapy (with proteasome inhibitor or daratumumab) and costimulation blockade (with belatacept).MethodsWe reviewed five highly sensitized patients who underwent desensitization
-
The impact of high volumes of COVID‐related lung transplant on waitlist mortality for non‐COVID candidates in the United States Clin. Transplant. (IF 2.1) Pub Date : 2024-02-19 Maxwell Marshall, Joshua Diamond, Hilary Goldberg, Andrew Courtwright
Some patients with coronavirus disease 19 (COVID) develop serious, irreversible lung disease, including acute respiratory distress syndrome or pulmonary fibrosis. For select candidates, lung transplant is the only option to improve quality and length of life. Because of the severity of end‐stage COVID‐related lung disease, these candidates receive high allocation priority in the United States, including
-
Using HCV‐viremic organs for lung transplantation does not confer higher rejection rates compared to HCV‐negative organs Clin. Transplant. (IF 2.1) Pub Date : 2024-02-19 Kamyar Afshar, Elizabeth Schonhoft, Jade Kozuch, Aarya Kafi, Gordon Yung, Travis Pollema, Eugene Golts, Saima Aslam
BackgroundNational data demonstrate that hepatitis C virus (HCV)—infected organ donors are increasingly being used in the US, including for lung transplantation. We aimed to assess whether there were any differences in the acute or chronic rejection rates at 1 year following lung transplantation from HCV‐viremic versus uninfected donors.MethodsWe retrospectively reviewed all lung transplant recipients
-
Pain trajectories after bilateral orthotopic lung transplantation surgery performed via a clamshell incision Clin. Transplant. (IF 2.1) Pub Date : 2024-02-19 Negmeldeen Mamoun, Morgan A. Rosser, Michael Manning, Karthik Raghunathan, Sharon McCartney, Sachin Mehta, Krista Ingle, Brandi Bottiger
IntroductionThe nature, intensity, and progression of acute pain after bilateral orthotopic lung transplantation (BOLT) performed via a clamshell incision has not been well investigated. We aimed to describe acute pain after clamshell incisions using pain trajectories for the study cohort, in addition to stratifying patients into separate pain trajectory groups and investigating their association with
-
Heart transplantation from COVID‐positive donors with 6‐month follow‐up: A case series Clin. Transplant. (IF 2.1) Pub Date : 2024-02-19 Christina Tran, Anureet Malhotra, Tarun Dalia, Harsh Mehta, Sahej Arora, Ilham Boda, Hassan Farhoud, Grace Noonan, Albert Eid, Andrija Vidic, Zubair Shah
BackgroundData on long term outcomes in heart transplant recipients from Coronavirus disease 2019 (COVID‐19) positive donors are limited.Methods and resultsWe present a series of nine patients who underwent heart transplants from COVID‐19 PCR‐positive donors between November 2021 to August 2022 with mean follow‐up of 12.12 ± 3 months. All the recipients received two doses of COVID‐19 vaccine and had
-
Improving value delivery in living donor kidney transplant through process improvement Clin. Transplant. (IF 2.1) Pub Date : 2024-02-11 Jorge Sanchez Garcia, Chloe Tien, Megan Fife, Brittany Dillon, Sean Dow, Zubair Zafar, Donald Morris, Sanjiv Anand
Living donor kidney evaluation has substantial time variations with significant intercenter variation. One-day donor evaluation has shown to be clinically efficient and improve transplant rates. However, patients’ perception of 1-day evaluation is unknown. We hypothesized that 1 day LKD evaluation will improve patient satisfaction and improve living donation rates.
-
Pharmacotherapy in the heart transplant recipient: A primer for nurse clinicians and pharmacists Clin. Transplant. (IF 2.1) Pub Date : 2024-02-11 Meg Fraser, Robert L. Page, Sheryl Chow, Tamas Alexy, Laura Peters
Heart transplantation (HT) is the definitive treatment for eligible patients with end-stage heart disease. A major complication of HT is allograft rejection which can lead to graft dysfunction and death. The guiding principle of chronic immunosuppression therapy is to prevent rejection of the transplanted organ while avoiding oversuppression of the immune system, which can cause opportunistic infections
-
Alemtuzumab versus anti-thymocyte globulin in kidney transplant recipients receiving a rapid steroid withdrawal regimen Clin. Transplant. (IF 2.1) Pub Date : 2024-02-02 Rachel A. Rikard, Laura M. Chargualaf, Carolyn Coulter, Eric T. Weimer, John L. Schmitz, Elizabeth S. Kotzen, Alyson Prom, Alexander H. Toledo, Kristen R. Szempruch
In kidney transplant recipients (KTRs), steroid-free maintenance regimens are used to minimize the negative impact of steroid use. Studies comparing alemtuzumab (ALZ) and anti-thymocyte globulin (ATG) with rapid steroid withdrawal are limited. The aim of this study was to assess a composite outcome of incidence of de novo donor specific antibodies (dnDSAs), biopsy proven rejection (BPAR), graft failure
-
Low-dose tissue plasminogen activator is safe and effective in treating major intracardiac thrombosis in liver transplant recipients Clin. Transplant. (IF 2.1) Pub Date : 2024-02-02 Christine Nguyen-Buckley, Victor Xia, Mansi Sheth, Tristan Grogan, Sara Arastoo, Jennifer Scovotti, Fady Kaldas, Christopher Wray
Major intracardiac thrombosis is an uncommon event during liver transplantation and has a high mortality rate. Given concerns for hemorrhage in liver transplantation with higher doses, low-dose tissue plasminogen activator has been proposed as a treatment that rapidly leads to localized clot lysis and resolution of right ventricular failure.
-
“You don't know what you don't know”: A qualitative study of informational needs of patients, family members, and living donors to inform transplant system metrics Clin. Transplant. (IF 2.1) Pub Date : 2024-01-29 Allyson Hart, Cory R. Schaffhausen, Warren T. McKinney, Kristina Gonzales, Julia Perugini, Jon J. Snyder, Keren Ladin
Informational needs and potential use of transplant metrics, especially among patients, remain understudied and a critical component of the transplant community's commitment to patient-centered care. We sought to understand the perspectives and needs of patients, family members/caregivers, living donors, and deceased donor family members.
-
Effects of WuZhi preparations on tacrolimus in pediatric and adult patients carrying the CYP3A5*1 allele of heart transplant during the early period after transplantation Clin. Transplant. (IF 2.1) Pub Date : 2024-01-27 Li Liu, Ying Zhou, Xiao Huang, Hefen Chen, Zhujun Gong, Jing Zhang, Fang Zeng, Hong Zhou, Yu Zhang
Wuzhi preparations (WZP) are commonly administrated with tacrolimus (TAC) in China to improve the liver function and increase the exposure of TAC. This study aims to investigate the effects of WZP on TAC in pediatric heart transplantation (HTx) patients carrying the CYP3A5*1 allele during the early period after transplantation and also make a comparison with these effects in adult recipients.
-
The influence of socioeconomic deprivation on outcomes in transplant patients infected with SARS-CoV-2 in Wales Clin. Transplant. (IF 2.1) Pub Date : 2024-01-23 Georgios Koimtzis, Georgios Geropoulos, Christopher Chalklin, Ioannis Karniadakis, Laszlo Szabo, Mohammed Adel Ilham, Michael Stephens, Argiris Asderakis, Usman Khalid
SARS-CoV-2 infection has had a significant impact on vulnerable individuals including transplant patients. Socioeconomic deprivation negatively affects outcomes of many health conditions. The aim of this study was to evaluate the effect of socioeconomic deprivation on the incidence and severity of SARS-CoV-2 infection among Welsh transplant patients.
-
Association between donor kidney cysts and donor and recipient outcomes after living donor kidney transplantation Clin. Transplant. (IF 2.1) Pub Date : 2024-01-23 Brendan R. Emmons, Joel T. Adler, Pedro Rodrigo Sandoval, Kristen L. King, Miko Yu, David C. Cron, Sumit Mohan, Lloyd E. Ratner, Syed Ali Husain
Incidental kidneys cysts are typically considered benign, but the presence of cysts is more frequent in individuals with other early markers of kidney disease. We studied the association of donor kidney cysts with donor and recipient outcomes after living donor kidney transplantation.
-
Peak insulin drip rate associated with decreased infections post-solid organ transplant Clin. Transplant. (IF 2.1) Pub Date : 2024-01-23 Gautham Upadrasta, Alison Affinati, Smita Kumar, Henry Zelada, Candace Fulkerson, Suruchi Gupta, Teresa Pollack, Adin-Cristian Andrei, Diana Johnson Oakes, Kathleen Schmidt, Ashley Therasse, Kathleen Grady, Duc Pham, Jane Wilcox, Josh Levitsky, Neehar Parikh, Daniela Ladner, Grazia Aleppo, Mark E. Molitch, Amisha Wallia
Infection and rejection outcomes were retrospectively analyzed in patients following liver transplant and separately following heart transplant with patients being stratified by their severity of immediate postoperative insulin resistance as measured by the peak insulin drip rate that was required to reduce glucose levels. For each group, these peak insulin drip rates were divided into quartiles (Q)
-
Long-term survival of ischemic cardiomyopathy patients with severe left ventricular dysfunction after CABG vs heart transplantation: A single center retrospective analysis Clin. Transplant. (IF 2.1) Pub Date : 2024-01-23 Tailong Zhang, Matiullah Masroor, Chen Jiang, Li Xu, Yixuan Wang, Cheng Deng, Nianguo Dong
There are no guidelines on the surgical management for ischemic cardiomyopathy (ICM) patients with severe left ventricular dysfunction. The present study aims to assess the long-term survival of these patients treated with two different surgical techniques, coronary artery bypass grafting (CABG) and heart transplantation (HTx).
-
Lung transplantation in HIV seropositive recipients: An analysis of the UNOS registry Clin. Transplant. (IF 2.1) Pub Date : 2024-01-23 Jack K. Donohue, Ernest G. Chan, Sarah Clifford, John P. Ryan, Masashi Furukawa, Ghady Haidar, Alessandro Bertani, Chadi A. Hage, Pablo G. Sanchez
Experience with lung transplantation (LT) in patients with human immunodeficiency virus (HIV) is limited. Many studies have demonstrated the success of kidney and liver transplantation in HIV-seropositive (HIV+) patients. Our objective was to conduct a national registry analysis comparing LT outcomes in HIV+ to HIV-seronegative (HIV−) recipients.
-
Regional anesthesia for transplantation surgery - A White Paper Part 2: Abdominal transplantation surgery Clin. Transplant. (IF 2.1) Pub Date : 2024-01-18 Michael Ander, Neal Mugve, Cara Crouch, Cale Kassel, Kyota Fukazawa, Robert Isaak, Ranjit Deshpande, Charles McLendon, Jiapeng Huang
Transplantation surgery continues to evolve and improve through advancements in transplant technique and technology. With the increased availability of ultrasound machines as well as the continued development of Enhanced Recovery after Surgery (ERAS) protocols, regional anesthesia has become an essential component of providing analgesia and minimizing opioid use perioperatively. Many centers currently
-
Human tracheal transplantation: A systematic review of case reports Clin. Transplant. (IF 2.1) Pub Date : 2024-01-19 Vincenzo Verzeletti, Marco Mammana, Giovanni Zambello, Andrea Dell'Amore, Federico Rea
Patients with long-segment airway stenosis not amenable to conventional surgery may benefit from tracheal transplantation. However, this procedure has been only anecdotally reported, and its indications, techniques, and outcomes have not been extensively reviewed.
-
Risk factors for renal dysfunction after isolated intestinal transplantation Clin. Transplant. (IF 2.1) Pub Date : 2024-01-19 Dagny von Ahrens, Andrew D. Santeusanio, Alan D. Weinberg, Jang Moon, Kishore R. Iyer
Kidney dysfunction is a known complication of intestinal transplantation; however, the rate of development and risk factors for chronic kidney disease (CKD) remain poorly defined.
-
Comparison of postoperative ascites replacement strategies on time to first flatus after living donor liver transplantation: Albumin vs. lactated Ringer's solution Clin. Transplant. (IF 2.1) Pub Date : 2024-01-18 Seung-Young Oh, Hye-Young Woo, Leerang Lim, Hyunjae Im, Hannah Lee, Jeong-Moo Lee, Suk Kyun Hong, YoungRok Choi, Nam-Joon Yi, Kwang-Woong Lee, Kyung-Suk Suh, Ho Geol Ryu
There is insufficient evidence regarding the optimal regimen for ascites replacement after living donor liver transplantation (LT) and its effectiveness. The aim of this study is to evaluate the impact of replacing postoperative ascites after LT with albumin on time to first flatus during recovery with early ambulation and incidence of acute kidney injury (AKI).
-
Immune outcomes of lung transplant recipients with different cytochrome P450 3A5 phenotypes after discontinuation of voriconazole antifungal prophylaxis Clin. Transplant. (IF 2.1) Pub Date : 2024-01-19 Zoe H. Tu, Brett J. Pierce, Taylor Pasley, Aaron Hutchins, Howard Huang
Tacrolimus forms the backbone of immunosuppression regimens in lung transplant recipients (LTRs). It is extensively metabolized by cytochrome P450 (CYP) 3A5 enzymes, of which polymorphisms can significantly affect tacrolimus dose requirements. It is unknown how coadministration of tacrolimus with voriconazole, a potent CYP3A5 inhibitor, affects rejection rates or empiric dose adjustments needed after
-
Fractal characteristics of the trabecular pattern of the mandible in patients with renal transplantation Clin. Transplant. (IF 2.1) Pub Date : 2024-01-19 Murat Altunok, Özkan Miloğlu, Hasan Doğan, Ahmet Berhan Yılmaz, Abdullah Uyanık, Erdem Çankaya
In this study, we examined the mandibular trabecular bone structures by performing fractal dimension (FD) analysis in patients who underwent renal transplantation (RTx).
-
A pragmatic tool to screen for pre-transplant cognitive impairment among potential candidates for liver transplant Clin. Transplant. (IF 2.1) Pub Date : 2024-01-19 Mayan S. Teles, Jessica M. Ruck, Alexa Jefferis, Sherif Helmy, Esther S. Oh, Emily C. Murriel, Jennifer C. Lai, Elizabeth A. King
Cognitive impairment (CI) among liver transplant (LT) candidates is associated with increased risk of waitlist mortality and inferior outcomes. While formal neurocognitive evaluation is the gold standard for CI diagnosis, the Montreal Cognitive Assessment (MoCA) is often used for first-line cognitive screening. However, MoCA requires specialized training and may be too lengthy for a busy evaluation
-
Letter to the editor: Poor sensitivity of anti-nucleocapsid antibody in detecting prior COVID-19 in vaccinated solid organ transplant recipients Clin. Transplant. (IF 2.1) Pub Date : 2024-01-19 Jennifer L. Alejo, Teresa PY Chang, Sarah Frey, Goutham A. Nair, Aura T. Abedon, Zeba Nauroz, Andrew H. Karaba, Robin K. Avery, Aaron A. R. Tobian, William A. Clarke, Jacqueline M. Garonzik-Wang, Dorry L. Segev, Allan B. Massie, William A. Werbel
1 INTRODUCTION Reliable clinical tests to identify prior severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection may inform seroprevalence studies, post-acute COVID-19 diagnoses (“Long COVID”), and study eligibility. Although antibody against the nucleocapsid protein of SARS-CoV-2 (anti-N) is a very sensitive biomarker in the unvaccinated general population, anti-N seroconversion rates
-
Kidney transplantation using ipsilateral arterial and contralateral venous anastomosis in a patient with failing vascular access Clin. Transplant. (IF 2.1) Pub Date : 2024-01-18 Donnacha Hogan, Sarah Marie Norton, Niall Francis Davis, Ponnusamy Mohan
Herein, we describe our surgical technique and outcome of a kidney transplant in a patient with failing vascular access. A right donor kidney was transplanted into the right iliac fossa with an end-to-side arterial anastomosis to the ipsilateral right common iliac artery and end-to-side venous anastomosis to the contralateral left common iliac vein. The possibility of performing an ipsilateral arterial
-
Safety and utility of panniculectomy in renal transplant candidates and end stage renal disease patients Clin. Transplant. (IF 2.1) Pub Date : 2024-01-12 Matteo Laspro, Thor S. Stead, Brooke Barrow, Hilliard T. Brydges, Ogechukwu C. Onuh, Bruce E. Gelb, Ernest S. Chiu
As the obesity crisis in the United States continues, some renal transplantation centers have liberalized their BMI criteria necessary for transplant eligibility. More individuals with larger body-habitus related comorbidities with End-Stage Renal Disease (ESRD) now qualify for renal transplantation (RT). Surgical modalities from other fields also interact with this patient population.
-
Outcomes of kidney transplantation in patients with IgA nephropathy based on induction: A UNOS data analysis Clin. Transplant. (IF 2.1) Pub Date : 2023-12-21 Emmanuel Albert Aydin-Ghormoz, Jason Perlmutter, Naoru Koizumi, Jorge Ortiz, Geovani Faddoul
IgA nephropathy (IgAN) can cause end-stage kidney disease (ESKD). This study assesses the impact of induction and maintenance immunosuppression on IgAN recurrence, graft survival, and mortality in living and deceased donor kidney transplants (LDKT and DDKT).
-
Prevalence of cognitive impairment in liver transplant recipients Clin. Transplant. (IF 2.1) Pub Date : 2023-12-19 Kacey Berry, Jessica M. Ruck, Fawzy Barry, Amy M. Shui, Aly Cortella, Dorothea Kent, Srilakshmi Seetharaman, Randi Wong, Lawren VandeVrede, Jennifer C. Lai
Liver transplant (LT) recipients have a high burden of cognitive impairment risk factors identified in other populations, yet little work has explored cognition in the United States LT population. We characterized prevalence of cognitive impairment (CI) in LT recipients pre-LT and ≥3 months post-LT. Adult LT recipients with cirrhosis but without active pre-LT hepatic encephalopathy (HE) were screened
-
Utilization of aquapheresis among hospitalized patients with end-stage liver disease: A case series and literature review Clin. Transplant. (IF 2.1) Pub Date : 2023-12-18 James F. Crismale, Tonia Kim, Thomas D. Schiano
Third-spacing of fluid is a common complication in hospitalized patients with decompensated cirrhosis. In addition to ascites, patients with advanced cirrhosis may develop significant peripheral edema, which may limit mobility and exacerbate debility and muscle wasting. Concomitant kidney failure and cardiac dysfunction may lead to worsening hypervolemia, which may ultimately result in pulmonary edema
-
Impact of Share 35 liver transplantation allocation in Australia and New Zealand Clin. Transplant. (IF 2.1) Pub Date : 2023-12-13 Michael A. Fink, Paul J. Gow, Geoffrey W. McCaughan, Peter Hodgkinson, John Chen, John McCall, Bryon Jaques, Michael Crawford, Simone I. Strasser, Winita Hardikar, Mark Brooke-Smith, Graham Starkey, Gary P. Jeffrey, Ed Gane, Michael Stormon, Helen Evans, Caroline Tallis, Amanda J. Byrne, Robert M. Jones
Patients with high model for end-stage liver disease (MELD) scores waiting for liver transplantation in Australia and New Zealand (ANZ) have had limited access to deceased donor livers and therefore binational sharing of livers, for patients with a MELD score ≥35 was introduced in February 2016. Waiting list mortality, post-transplant outcomes and intention-to-treat survival were compared between patients